---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-016245"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:11:12.969954+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q1 revenue $41.6M (+162% YoY); raises FY23 guidance to $160-170M

## Summary
- Q1 2023 revenue $41.6M (+162% YoY from $15.9M) driven by NOP adoption and OCS Liver/Heart sales.
- Gross margin 69% vs 76% in Q1 2022 and 66% in Q4 2022.
- Net loss improved to $2.6M from $10.6M in Q1 2022.
- Operating expenses $30.9M (incl. $3.9M stock comp) vs $21.5M (incl. $2.3M) in prior year.
- FY2023 revenue guidance raised to $160-170M (71-82% growth) from prior $138-145M.

## SEC filing metadata
- accession: 0000950170-23-016245
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/0000950170-23-016245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/tmdx-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-016245
- JSON: https://secwatch.observer/filing/0000950170-23-016245.json
- Plain text: https://secwatch.observer/filing/0000950170-23-016245.txt

## Key facts
- Earnings Releases
  TransMedics Group, Inc. reported the quarter ended March 31, 2023 results: revenue $41.6 million, net income $2.6 million, EPS $(0.34) per diluted share. Guidance raised.
  - Period: the quarter ended March 31, 2023
  - Revenue: $41.6 million
  - Net income: $2.6 million
  - EPS: $(0.34) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: TransMedics Reports First Quarter 2023 Financial Results Andover, Mass. – May 1, 2023 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights ▪ Net revenue of $41.6 million in the first quarter of 2023, a 162% increase compared to the first quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1756262/000095017023016245/0000950170-23-016245-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.